Stocks rose Friday, with Wall Street headed to a fourth week of gains ahead of the long holiday weekend.» Read More
So, I thought I'd be spending today monitoring the webcast of the FDA Advisory Committees that are meeting to decide whether doctors should use less of the anemia drugs from Amgen and Johnson & Johnson to treat kidney dialysis patients.
Wall Street is counting down to next week's Fed meeting and not much else is influencing trading. Stocks are readying for a higher opening as investors wait for a speech from Fed Chairman Ben Bernanke later this morning and watch the action at OPEC.
Patients given drug-coated stents after an acute heart attack are nearly five times more likely to die six months to two years later than those with bare metal forms of the arterial scaffolding, research showed on Tuesday.
A U.S. court dismissed some claims in a lawsuit filed by Johnson & Johnson over its failed bid for Guidant.
There are two kinds of companies in the market – cyclical and secular. One of the most important moves in the game is to know when to shift money from one to the other.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Warren Buffett's Berkshire Hathaway has just revealed its portfolio holdings for the second quarter. New additions: Bank of America and Dow Jones, plus increased stakes in some healthcare names.
At CNBC we use -- among others -- a couple of primary business news wire services -- NewsEdge, part of Thomson, and Relegence, part of AOL.
Late Thursday, ImClone Systems announced it has finally hired a permanent CEO. It'd been without one for about two years. The biotech company which makes the cancer drug Erbitux and became reluctantly famous in the Martha Stewart stock-trading case tapped a guy named John Johnson for the role.
Johnson & Johnson, the drug/medical device/consumer health products company reeling from a plunge in sales of its anemia drug, Procrit, and its drug-coated stent, Cypher, is going to court. Not to defend a lucrative pharmaceutical patent, but to get The Red Cross to stop using its red cross logo on certain marketed products like humidifiers and grooming tools.
Johnson & Johnson, the pharmaceutical giant which uses a Red Cross as its trademark, filed a lawsuit Wednesday against the American Red Cross, demanding that the charity halt the use of the red cross symbol on products it sells to the public.
The market's wild swings are expected to continue through the summer, analysts say, but investors should take advantage of the volatility instead of fearing it. "There's no reason to think these 100, 200-point swings won't continue," said Rob Brown, chief investment officer at Genworth Financial. "That provides an investment opportunity."
ZymoGenetics, Cameco and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
As several of the major pharmaceutical companies struggle through a period of a relative dearth of big, new products, the job casualties and the share buybacks are piling up this earnings season. Today, Sanofi-Aventis is joining the group. The French drugmaker announced it will buy back more than $4 billion of its stock and get rid of even more sales reps.
Johnson & Johnson said Tuesday it planned to eliminate 3 percent to 4 percent of its global work force of about 120,500 people as part of a plan to improve its cost structure. The cost-cutting plan is expected to generate pretax cost savings of $1.3 billion to $1.6 billion in 2008, the diversified health care company said.
With stocks in rally mode, it's appropriate to drill down for answers as well as take a look at some key sectors.
Second-quarter earnings are mostly beating expectations so far, and much of that gain can be tied to growth overseas. For that reason, many analysts believe investors should be looking at big multinational companies with strong foreign business.
Investors picked up where they left off a week ago, as stock prices hurtled to new highs with the Dow Industrials setting another milestone, but a Friday selloff kind of spoiled the mood.
Caterpillar, Johnson & Johnson, Toyota and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
The Dow Jones Industrial Average closed at a record high, but slipped below 14,000 after trading above the milestone earlier in the session. Traders remained optimistic that the market will power higher. "We're not going to stop at 14,000; it's just an arbitrary number," said Gordon Charlop, president of Walter J. Dowd.
Johnson & Johnson Tuesday said second-quarter profit rose on higher sales of medical devices and prescription drugs, beating Wall Street expectations on especially strong demand in overseas markets.